What is the most recent earnings date for DLB stock?
DOLBY LABORATORIES INC-CL A (DLB) last reported earnings on 1/29/2026.
NYSE:DLB • US25659T1079
Past quarterly earnings results for DOLBY LABORATORIES INC-CL A (DLB), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q1 2026 | 1.06 | 0.89 | 19.71% | -7.02% | 346.706M | 335.63M | 3.30% | -2.88% |
| Q4 2025 | 0.99 | 0.71 | 40.03% | 22.22% | 307.024M | 307.74M | -0.23% | 0.73% |
| Q3 2025 | 0.78 | 0.72 | 8.26% | 9.86% | 315.546M | 308.29M | 2.35% | 9.25% |
| Q2 2025 | 1.34 | 1.28 | 4.74% | 5.51% | 369.561M | 380.15M | -2.79% | 1.38% |
| Q1 2025 | 1.14 | 1.06 | 7.16% | 12.87% | 356.999M | 349.61M | 2.11% | 13.13% |
| Q4 2024 | 0.81 | 0.70 | 15.12% | 24.62% | 304.806M | 311.02M | -2.00% | 4.90% |
| Q3 2024 | 0.71 | 0.60 | 19.15% | 29.09% | 288.818M | 289.04M | -0.08% | -3.20% |
| Q2 2024 | 1.27 | 1.21 | 5.37% | 0.79% | 364.523M | 363.04M | 0.41% | -3.02% |
| Q1 2024 | 1.01 | 0.87 | 16.28% | -9.01% | 315.574M | 316M | -0.13% | -5.77% |
| Q4 2023 | 0.65 | 0.53 | 22.19% | 20.37% | 290.562M | 293.1M | -0.87% | 4.44% |
| Q3 2023 | 0.55 | 0.56 | -0.99% | -19.12% | 298.37M | 304.66M | -2.06% | 3.03% |
| Q2 2023 | 1.26 | 0.98 | 27.95% | 36.96% | 375.891M | 353.34M | 6.38% | 12.41% |
| Q1 2023 | 1.11 | 0.79 | 40.00% | 9.90% | 334.9M | 309.62M | 8.16% | -4.75% |
| Q4 2022 | 0.54 | 0.61 | -10.89% | -6.90% | 278.2M | 308.28M | -9.76% | -2.39% |
| Q3 2022 | 0.68 | 0.59 | 15.09% | -4.23% | 289.6M | 296.98M | -2.49% | 0.98% |
| Q2 2022 | 0.92 | 0.82 | 11.54% | 1.10% | 334.4M | 335.84M | -0.43% | 4.63% |
| Q1 2022 | 1.01 | 1.07 | -5.88% | -31.76% | 351.6M | 365.84M | -3.89% | -9.82% |
| Q4 2021 | 0.58 | 0.57 | 2.09% | 28.89% | 285M | 302.95M | -5.93% | 5.09% |
| Q3 2021 | 0.71 | 0.48 | 47.99% | -17.44% | 286.8M | 281.58M | 1.85% | 16.16% |
| Q2 2021 | 0.91 | 0.67 | 35.15% | -12.50% | 319.6M | 297.23M | 7.53% | -9.15% |
| Q1 2021 | 1.48 | 1.05 | 40.36% | 214.89% | 389.9M | 348.79M | 11.79% | 33.57% |
| Q4 2020 | 0.45 | 0.34 | 31.82% | - | 271.2M | 246.88M | 9.85% | - |
| Q3 2020 | 0.86 | 0.27 | 213.05% | - | 246.9M | 234.94M | 5.09% | - |
| Q2 2020 | 1.04 | 1.10 | -5.53% | - | 351.8M | 364.97M | -3.61% | - |
| Q1 2020 | 0.47 | 0.50 | -5.80% | - | 291.9M | 288.67M | 1.12% | - |
Notes
DOLBY LABORATORIES INC-CL A (DLB) last reported earnings on 1/29/2026.
DOLBY LABORATORIES INC-CL A (DLB) beat EPS estimates and beat revenue estimates in the most recent quarter.
In the last 4 quarters, DOLBY LABORATORIES INC-CL A (DLB) has beaten EPS estimates in 4 out of 4 releases.